Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 337

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 337
---
 holders of Series A Preferred Stock.

In the three months ended September 30, 2024,
7,005 shares of Series A Preferred Stock were converted into 1,089,489 shares of Common Stock. As of September 30, 2024, there were 3,075
remaining shares of Series A Preferred Stock, which were convertible into 621,966 shares of Common Stock.

<div align='center'>F-16</div>

Successor Series B Convertible Preferred Stock

The Company designated 626 shares of its authorized
preferred stock as Series B Preferred Stock and established the rights, preferences and privileges of the Series B Preferred Stock pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the “Series
B Certificate of Designations” and, together with the Series A Certificate of Designations, the “Certificates of Designations”),
as summarized below. Except as set forth below, the Series B Preferred Stock has terms and provisions that are identical to those of
the Series A Preferred Stock.

On April 1, 2024, we consummated a private placement
of 626 shares of the Company Series B Preferred Stock, pursuant to the Securities Purchase Agreement, dated March 28, 2024, by and among
us and certain accredited investors (the “Additional Investors” and, together with the Initial Investors, the “PIPE
Investors”), for aggregate cash proceeds to us of approximately $0.5 million. Such private placement closed on April 1, 2024.

The holders of the Series B Preferred Stock have
no voting rights.

The Series B Preferred Stock ranks pari passu
with the Series A Preferred Stock.

Due to delayed filing and declaration of effectiveness
relative to the deadlines defined in the Registration Rights Agreement, the Company accrued for an aggregate $37,330 penalty as of June
30, 2024, payable in cash to the holders of Series B Preferred Stock.

In the three months ended September 30, 2024,
140 shares of Series B Preferred Stock were converted into 12,440 shares of Common Stock. As of September 30, 2024, there were 486 remaining
shares of Series B Preferred Stock, which were convertible into 98,301 shares of Common Stock.

Successor Series C Convertible Preferred Stock

The Company designated 2,853 shares of its authorized
preferred stock as the Series C Preferred Stock and the rights, preferences and privileges of the Series C